Drug development company Prima Biomed has told the market its first year research programs into cancer immunotherapy and anti-inflammatory treatments had met or exceeded their milestones. [ + ]

Australia's place in the futuristic world of nanotechnology has been further cemented with the set up of Dendrimer Nanotechnologies (DNT) now complete. [ + ]

Two ex-CSIRO scientists who have spent four years quietly commercialising Australian expertise in livestock DNA testing are in the midst of a US sales boom. [ + ]

Sydney-based biotech Peptech has gained United States patent protection for its tumour necrotising factor (TNF) antibodies, priming the company for its next growth phase. [ + ]

"It's time for Australian industry to wake up to the power of light," says Sir Peter Williams, President of the UK Institute for Physics.

Australian researchers have welcomed the National Health and Medical Research Council's draft guidelines on xenotransplantation, released yesterday. [ + ]

A Western Australian oil and metal exploration company has gathered some of the top names in Australian science as it moves towards rebirth as a biotech. [ + ]

Victoria has beaten a host of other nations to win the right to stage an international synchrotron conference in 2005. [ + ]

Natural insecticide developer BioProspect has reached a second deal over rights to test its new product. [ + ]

Melbourne's St Vincent's Institute of Medical Research has attracted a $2 million Victorian government grant to boost its research facilities. [ + ]

A novel compound from the venom of a cone shell marine snail found on the Great Barrier Reef may have a use as a drug to treat chronic pain, according to scientists from the University of Melbourne and the National Ageing Research Institute. [ + ]

Ethical concerns over issues like the use of embryonic stem cells in research could be addressed in the patent system, a new paper has argued. [ + ]

Gene discovery group Bionomics plans to lodge an international patent covering almost 150 gene variants related to diseases including Alzheimer's, depression, epilepsy and Parkinson's. [ + ]

A leukaemia drug developed by Adelaide biotech BresaGen will go back to the drawing board after it was found not to be as effective as previously thought against one form of the disease. [ + ]

Cardia Technologies subsidiary Bioglobal has bought intellectual property from Queensland's Department of Primary Industries relating to blowfly attract and kill technology. [ + ]